Neurological disorders in Northern Tanzania: A 6-year prospective hospital-based case series

William P Howlett¹,², Sarah J Urasa¹, Venance P Maro¹, Richard W Walker³, Kajiru G Kilonzo¹, Patrick J Howlett¹, Marieke CJ Dekker¹

1. Kilimanjaro Christian Medical Centre, Moshi, Kilimanjaro, Tanzania.
2. Centre for International Health University of Bergen, Bergen Norway.
3. Department of Medicine, North Tyneside General Hospital, Rake Lane, North Shields, Tyne, and Wear NE29 8NH.
4. Royal Brompton and Harefield Hospital Trust Fulham Road, London, SW3 6HP.

Abstract

Background: The burden of neurological disorders is large and altered by the HIV epidemic.

Objectives: We describe the pattern of neurological disorders and their association with HIV infection in adult patients attending a consultant hospital in Northern Tanzania.

Methods: In this prospective cross-sectional study, we collected data on adult neurological referrals over a 6-year period between 2007-13. The odds of HIV infection, across neurological categories adjusted for age and sex, was calculated.

Results: Of 2037 participants, 54.8% were male and 45.2% were female. The median age of participants was 43 years. The results for HIV screening were available for 992/2037 (48.7%) patients, of whom 306 (30.8%) were seropositive. The most frequent neurological disorders were cerebrovascular disease (19.9%), paraplegia (13.6%), and peripheral neuropathies (8%). Taken together CNS infection accounted for 278/2037 (13.6%). The adjusted odds (aOR) of HIV infection was highest amongst infections; brain abscesses (aOR 107, 95% CI 35.1-470.4) and meningitis/encephalitis (aOR 40.1, 95% CI 13.6-172.9), but also raised in cerebrovascular disease, paraplegia, peripheral neuropathies, cranial nerve palsies, seizures, cerebellar disorders, movement disorders, motor neuron disease and headache.

Conclusion: The main pattern of neurological disorders in Northern Tanzania is presented. The odds of HIV infection was highest in CNS infections and in a wide range of non-communicable neurological disorders.

Keywords: Tanzania; neurological; disorder; neurological disease; hospital; HIV

DOI: https://dx.doi.org/10.4314/ahs.v22i1.34

Cite as: Howlett WP, Urasa SJ, Maro VP, Walker RW, Kilonzo KG, Howlett PJ, et al. Neurological disorders in Northern Tanzania: A 6-year prospective hospital-based case series. Afri Health Sci. 2022;22(1):269-84. https://dx.doi.org/10.4314/ahs.v22i1.34

Background

The burden of neurological disorders (NDs) globally is large. In 2016 NDs were the second leading cause of death accounting for 9 million or 16.5% of all deaths and the leading cause of disability-adjusted life years (DALYs), accounting for 276 million or 11.6% of all DALYs with stroke, migraine, epilepsy, meningitis and dementia as main causes¹. In sub-Saharan Africa (SSA) NDs account for almost 30 million DALYs annually with stroke, meningitis, migraine, dementia and epilepsy as main causes¹,².

The pattern of NDs in SSA differs from that reported in high income countries, with infections, in particular human immunodeficiency virus (HIV) being more prevalent and neurodegenerative diseases less common³–⁶. In SSA NDs typically account for 18-25% of adult medical hospital admissions, the majority of whom either die in hospital or are discharged with disability³,⁵,⁷. The most common causes of neurological admissions in adults are stroke, infections, paraplegia, neuropathies, coma and seizures³–⁵,⁷. The most common NDs reported in outpatients are seizures/epilepsy, headache, stroke sequelae, neuropathies, movement disorders and neurodegenerative disorders⁸–¹¹.

Corresponding author:
William P Howlett,
P.O.Box 3010, Moshi Tanzania
Kilimanjaro Christian Medical Centre
Tel No: +255-687705599
Fax: 255-027-2754381
Email: williamhowlett.com@gmail.com

© 2022 Howlett WP et al. Licensee African Health Sciences. This is an Open Access article distributed under the terms of the Creative commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
NDs in SSA are also changing over time\(^1\). This is in part due to an increasing burden of non-communicable diseases (NCDs), reflecting more prevalent cerebrovascular risk factors, rapid urbanization and an increasingly ageing population\(^12,13\). While there has been a decrease in the frequencies of the more traditional central nervous system (CNS) infections including cerebral malaria, tetanus and bacterial meningitis, the increasing burden of HIV, now affecting over 26 million persons in SSA, is significantly altering the pattern of NDs. In 2016 WHO estimated that HIV was the second leading cause of death in SSA and responsible for approximately 720,000 deaths or over 8\% of all deaths in the Africa region. HIV affects the nervous system in 3 main ways\(^14, 15\). Firstly, through loss of cellular immunity resulting in CNS opportunistic processes mostly infections, secondly by direct infection resulting in HIV associated neurocognitive dysfunction (HAND), distal sensory neuropathy (DSN) and vacuolar myelopathy (VM) and lastly by autoimmunity resulting in inflammatory related NDs. However less well known are the overall effects of HIV on the existing patterns of NDs in SSA.

In this study we aim to describe the pattern of neurological disorders and specific neurological diseases in a large cohort of adult patients presenting with NDs, either admitted to hospital or attending neurological outpatient clinic and examine their association with HIV status. The information presented is intended to help in understanding the current burden and diversity of NDs in SSA and in particular their relation to HIV.

**Methods**

**Patient population**

This prospective cross-sectional hospital-based study was conducted in the medical department at Kilimanjaro Christian Medical Centre (KCMC). KCMC is a 600-bed referral consultant teaching hospital located in Moshi in the northern zone of Tanzania with a catchment population of over 16 million people. The study took place over a 6-year period from April 2007 to March 2013. It included both outpatients and inpatients presenting with neurological disorders who attended general medical/neurology outpatient clinic and/or admitted into the medical wards at KCMC under care of a general physician.

According to hospital policy, adult patients were classified as aged >13 years.

**Standard protocol approvals, registrations, and patient consents**

Permission to conduct the study was obtained from the head of the medical department and KCMC ethical committee, certificate number 817. Confidentiality was adhered to by using codes instead of names for identifying patients.

**Data collection**

During the study period patients referred for neurology consultation as inpatients or outpatients were examined by the lead author (WH), a consultant neurologist, and a neurological diagnosis was recorded at the time of examination which was either confirmed or amended based on clinical findings and investigations available. The series includes patients who received a formal and complete consultation. It does not include 2-month annual periods during which WH was absent or patients who had brief clinical reviews. Details of participants were recorded in a logbook and were later coded in an electronic database.

A single specific neurological disease diagnosis was made based on clinical, laboratory and radiological findings by WH. On the basis of this, participants were categorized into one of 19 groups of main neurological disorders chosen for their relevance to the study population. In situations where a case may satisfy two groups, for example meningitis/encephalitis and cranial nerve disorder, the disorder relating to the cause of the underlying pathology was given preference. Although in the majority of cases a single clinical neurological disorder was able to be diagnosed, in those cases where this was not possible the patient was categorized into a group describing the main presenting neurological disorder e.g., altered level of consciousness. The definitions used to classify the main neurological disorders are described in detail in Table 1.

A limitation in the study is that the site of examination was not recorded for all cases. While the majority of cases reported in the series were inpatients the findings in a representative sample of outpatients, n= 332 are presented in Figure 2.
| Diagnosis                                      | Definitions                                                                                                                                                                                                 |
|------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cerebrovascular disease                        | A clinical and/or radiological diagnosis including stroke, ischaemic and haemorrhagic, subarachnoid haemorrhage, and subdural haematoma.                                                                 |
| Infection: Meningitis/Encephalitis             | A clinical and/or laboratory/radiological diagnosis which includes cryptococcal, tuberculous, acute bacterial and viral meningitis/encephalitis.                                                                    |
| Infection: Intracerebral abscess               | A clinical and/or radiological diagnosis including toxoplasma, pyogenic, tuberculous, and non-differentiated brain abscess.                                                                                   |
| Infection: Cerebral Malaria/Tetanus/Others     | A clinical and/or laboratory/radiological diagnosis including, cerebral malaria tetanus and other CNS infections.                                                                                        |
| Paraplegia                                     | A clinical and/or radiological/laboratory diagnosis of non-traumatic causes including malignancy, transverse myelitis, Potts disease, syringomyelia, and other causes of paraplegia/quadriplegia of unknown aetiology. |
| Peripheral neuropathies                        | A clinical and/or laboratory diagnosis of sensory and motor peripheral neuropathy including Guillain Barré syndrome, subacute combined degeneration and mononeuritis multiplex and others. |
| Neuromuscular disorders                        | A clinical and/or laboratory diagnosis including myasthenia gravis, dermomyositis, muscular dystrophy, stiff person syndrome and others.                                                                      |
| Cranial nerve palsies                          | A clinical diagnosis including facial nerve palsy, optic neuritis, III, IV and V nerve palsy and others.                                                                                                     |
| Brain tumours                                  | Include clinically and/or radiologically categorized glioma, meningioma, and pituitary tumour. The general term tumour includes metastatic and diagnostically uncertain tumours.                                             |
| Seizure disorders                              | Include clinically diagnosed generalized and focal seizure disorders including epilepsy.                                                                                                                                                                           |
| Altered level of consciousness                 | A clinical diagnosis based on Glasgow Coma Scale and/or disorientation in time, person, or place, and includes acute confusional states, in the absence of alternative clear neurological diagnosis.                    |
| Movement disorders                             | A clinical diagnosis including dystonia, catatonia, involuntary movements, chorea, benign essential tremor, and writers’ cramp. The movement disorder Parkinson’s disease has its own category.                                   |
| Parkinson’s disease                            | A clinical diagnosis including Parkinson’s disease (PD) and Parkinson plus disorders.                                                                                                                                                                            |
| Cerebellar disorders                           | A clinical diagnosis categorized as idiopathic and hereditary including Friedreich’s ataxia.                                                                                                                                                                        |
| Motor neuron disease                           | A clinical diagnosis including amyotrophic lateral sclerosis, progressive muscular atrophy, primary lateral sclerosis, and pseudobulbar palsy.                                                                 |
| CNS demyelinating disease                      | A clinical and or radiological/laboratory diagnosis including neuromyelitis optica, multiple sclerosis and acute demyelinating encephalomyelitis.                                                        |
| Dementia                                       | A clinical diagnosis based on a laboratory/radiological investigations and minimal test score of <24/30 including Alzheimer’s, vascular and fronto temporal.                                                 |
| Headache                                       | A clinical diagnosis including tension headache, migraine, cluster, idiopathic intracranial hypertension, and others unclassified.                                                                           |
| Functional neurological disorders              | A clinical diagnosis including loss of neurological function, psychogenic non-epileptic attacks, movement disorders and others.                                                                              |
| Others                                         | A generic term in neurological disorder/disease categories that includes patients who were not specifically classified into specific neurological disease categories.                                              |

Laboratory and imaging investigations were those carried out routinely at the main laboratory and radiology departments at KCMC. HIV screening was done by two rapid HIV tests (Capillus/Bioline and Determine) and a positive result recorded if both were positive. Lumbar punctures were carried out as clinically indicated. Results included cell counts, protein and glucose, cryptococcal antigen (CrAg), Gram, ZN and India Ink stains and culture and sensitivities.
Electrophysiological investigations were unavailable at the time of the study. Imaging investigations included Computerized Tomography (CT). A CT scan of head was performed on patients suspected of having an abnormality but was limited due to availability and affordability. The CT scans were interpreted and reported by a qualified radiologist and in cases of diagnostic uncertainty scans were reviewed with WH. Magnetic resonance imaging (MRI) was unavailable at KCMC, although available via referral in exceptional cases. Specialized services including neurosurgery, neuro-oncology, advanced immunodiagnostics, and genetic confirmation were not available during the study period. Data was collected on age, sex, HIV result when performed, and specific neurological disorder/disease diagnostic category.

Analysis
The frequency and proportions of the specific diagnosis and disorder categories are described according to sex and median age. The results for percentages are rounded to one decimal place. An unadjusted logistic regression odds ratio of the association between HIV status and diagnosis was calculated. A second a priori adjusted model included age and sex. A Wald test for significance was calculated for each category. The category brain tumours was used as the baseline category for both models as this was the most well represented group with which HIV was not thought to be markedly associated. In addition, the HIV prevalence (3.6%) in this group was similar to Kilimanjaro regional adult seroprevalence of 3.8% reported in the Tanzanian 2011-12 HIV/AIDS indicator survey. On visual inspection, the age histograms and sex distribution of brain tumours were similar to the whole cohort. To compare those tested and not tested for HIV, a mean age and t-test was used for age, while unadjusted odds ratios and a Chi2 test was used to compare gender. Statistical analysis was performed using R software (version 3.5.1).

Results
Of 2,038 adult patients referred with a neurological disorder, 1 was missing a final diagnosis and was excluded from further study, while 22 patients with missing data on age and 4 on sex are included in the series. The median age of the study participants (n=2037) was 43 years, (Interquartile range (IQR) 29-58), and 54.8% were male and 45.2% were female. The results for HIV screening were available for 992/2037 (48.7%) patients, of whom 306 (30.8%) were reported seropositive. The frequency and demographics of main neurological disorders are presented in Table 2.

Table 2. Frequency and demographics of main neurological disorders (n=2037)

| Disorder category                  | Frequency (%) | *Median age in years (IQR) | *Male (%) | *Female (%) |
|-----------------------------------|---------------|----------------------------|-----------|-------------|
| Total                             | 2037          | 43 (29-58)                 | 1115 (54.8%) | 918 (45.2%) |
| Cerebrovascular disease           | 406 (19.9%)   | 55 (38.5-68)               | 252 (62.1%) | 154 (37.9%) |
| Infection: Intracerebral abscess  | 111 (5.4%)    | 37 (29.5-45)               | 45 (40.5%) | 66 (59.5%)  |
| Infection: Meningitis/Encephalitis| 110 (5.4%)    | 33 (25-40)                 | 66 (60%)   | 44 (40%)    |
| Infection: Cerebral Malaria/Tetanus/Others | 57 (2.8%) | 35 (21-49)                 | 40 (71.4%) | 16 (28.6%)  |
| Paraplegia                        | 278 (13.6 %)  | 45 (30-57.25)              | 165 (59.6%) | 112 (40.4%) |
| Peripheral neurapathies           | 163 (8%)      | 40 (29-53)                 | 73 (44.8%) | 90 (55.2%)  |
| Brain tumours                     | 161 (7.9%)    | 44.5 (31.75-61)            | 90 (56.25%) | 70 (43.75%) |
| Seizure disorders                 | 131 (6.4%)    | 32.5 (20.25-47.75)         | 62 (47.3%) | 69 (52.7%)  |
| Cranial nerve palsies             | 98 (4.8%)     | 41 (33-54)                 | 46 (46.9%) | 52 (53.1%)  |
| Movement disorders                | 90 (4.4%)     | 45 (27.25-61.75)           | 46 (51.1%) | 44 (48.9%)  |
| Altered level of consciousness    | 74 (3.6%)     | 38 (25-52)                 | 53 (71.6%) | 21 (28.4%)  |
| Neuromuscular disorders           | 72 (3.5%)     | 35 (21-45.5)               | 33 (45.8%) | 39 (54.2%)  |
| Motor neurone disease             | 68 (3.3%)     | 55 (41.75-66.25)           | 37 (55.2%) | 30 (44.8%)  |
| Parkinson’s disease               | 61 (3%)       | 62 (53-73)                 | 40 (65.6%) | 21 (34.4%)  |
| Functional neurological disorders  | 48 (2.4%)     | 20 (17-23.25)              | 14 (29.2%) | 34 (70.8%)  |
| Cerebellar disorders              | 39 (1.9%)     | 49 (36-58)                 | 21 (53.8%) | 18 (46.2%)  |
| Headache                          | 35 (1.7%)     | 33 (24-39.5)               | 15 (42.9%) | 20 (57.1%)  |
| Dementia                          | 20 (1%)       | 67 (59-73.25)              | 11 (55%)   | 9 (45%)     |
| Demyelinating disease             | 15 (0.7%)     | 19 (16-29.5)               | 6 (40%)    | 9 (60%)     |

Footnote *missing values, ages=20, sex=4.
The most frequent neurological disorder was cerebrovascular disease 19.9%, followed by paraplegia 13.6%. Taken together as an infection group; meningitis/encephalitis, brain abscess, cerebral malaria, tetanus, and others made up 13.6% of patients. A wide range of other neurological disorders were well represented including peripheral neuropathies 8%, brain tumours 7.9%, seizure disorders 6.4%. cranial nerve palsies 4.8%, movement disorders 4.4%, Parkinson's disease 3%, altered level of consciousness 3.6%, neuromuscular disorders 3.5%, motor neurone disease 3.3%, functional disorders 2.4% and cerebellar disease 1.9%. The frequency of headache 1.7%, dementia 1%, and demyelinating disorders 0.7% were low. The median age of these groups varied with disorder, with dementia 67 years, (IQR 59-73.25) Parkinson's disease 62 years, (IQR 53-73) and motor neuron disease 55 years, (IQR 41.75-66.25) affecting older age groups.

Patients with infectious CNS causes tended to have a lower median age of presentation ranging from 33 years, (IQR 25-40) in meningitis to 37 years, (IQR 29.5-45) in intracerebral abscess. Other groups with younger median ages of presentation included demyelinating disease 19 years, (IQR 16-29.5) functional disorders 20 years, (IQR 17-23.25) and neuromuscular disorders 35 years, (IQR 21-45.5).

The pattern of main neurological disorders by sex is outlined in Figure 1. The most notable differences in gender distribution was a predominance of males presenting with cerebrovascular disease 62.1%, Parkinson's disease 65.6%, meningitis/encephalitis 60%, tetanus 85.0% and paraplegia 59.6% Females were more frequently represented in functional disorders 70.8%, intracerebral abscess 59.5%, headache 57.1% and peripheral neuropathy 55.2%.

**Figure 1.** Neurological Disorders by sex (n=2037).
The pattern of neurological disorders in a selected outpatient cohort are presented in Figure 2.

The results for the analysis of the association of HIV with neurological disorders is presented in Table 3. Following adjustment for age and sex and in those tested for HIV a wide range of groups of NDs showed an increased odds of HIV when compared to the baseline group of brain tumours. Intracerebral abscesses were most strongly associated with HIV infection (aOR 107, 95% CI 35.1-470.7), followed by meningitis/encephalitis (aOR 40.1, 95% CI 13.6-172.9).

These groups also had the highest rates of HIV testing; 105/111 (94.6%) and 98/110 (89.1%) respectively. Large non-infectious disorders also had higher odds of HIV infection including cerebellar disorders (aOR 33.9, 95% CI 8.9-172.3), peripheral neuropathies (aOR 10.5, 95% CI 3.5-45.7), and cerebrovascular disease (aOR 5.6, 95% CI 1.9-23.9). Testing rates were lower in these groups, particularly cerebrovascular disease in whom 145/406 (35.7%) were tested.
### Table 3. Neurological disorders and their association with HIV (n=2037).

| Neurological diagnosis                      | Tested for HIV (%) | HIV positive (%) | Odds ratio for HIV positive (95% CI), n=973 | Adjusted odds ratio for HIV positive * (95% CI), n=958 | Adjusted p-value |
|---------------------------------------------|--------------------|-----------------|---------------------------------------------|--------------------------------------------------------|-----------------|
| Brain tumours                               | 83/161 (51.6%)     | 3 (3.6%)        | 1 [-]                                       | 1 [-]                                                   | 0.00            |
| Cerebrovascular disease                     | 145/406 (35.7%)    | 26 (17.9%)      | 5.8 (2-25)                                  | 5.6 (1.9-23.9)                                         | 0.01            |
| Infection: Intracerebral abscess            | 105/111 (94.6%)    | 84 (80%)        | 106.7 (35.4-465.6)                          | 107 (35.1-470.7)                                       | 0.00            |
| Infection: Meningitis/Encephalitis          | 98/110 (89.1%)     | 56 (51.1%)      | 35.6 (12.2-151.9)                           | 40.1 (13.6-172.9)                                      | 0.00            |
| Infection: Cerebral Malaria/Tetanus/Others  | 33/57 (57.9%)      | 9 (27.3%)       | 10 (2.7-47.8)                               | 11.1 (3-53.6)                                          | 0.00            |
| Paraplegia                                  | 131/2178 (47.1%)   | 25 (19.1%)      | 6.3 (2.1-27.1)                              | 6.2 (2.1-26.9)                                         | 0.00            |
| Peripheral neuropathies                     | 90/163 (55.2%)     | 27 (30%)        | 11.4 (3.8-49.4)                             | 10.5 (3.5-45.7)                                        | 0.00            |
| Seizure disorders                           | 39/131 (29.8%)     | 15 (38.5%)      | 16.7 (5-76.4)                               | 15.7 (4.6-73)                                          | 0.00            |
| Cranial nerve palsies                       | 62/98 (63.3%)      | 22 (35.5%)      | 14.7 (4.7-64.6)                             | 13.9 (4.4-61.3)                                        | 0.00            |
| Movement disorders                          | 29/90 (32.2%)      | 9 (31%)         | 12 (3.3-57.9)                               | 11.2 (3-54.3)                                          | 0.00            |
| Altered level of consciousness              | 34/74 (45.9%)      | 3 (8.8%)        | 2.6 (0.5-14.6)                              | 2.9 (0.5-16.8)                                         | 0.20            |
| Neuromuscular disorders                     | 40/72 (55.6%)      | 3 (7.5%)        | 2.2 (0.4-12.2)                              | 2.1 (0.4-11.8)                                         | 0.39            |
| Motor neurone disease                       | 35/68 (51.5%)      | 6 (17.1%)       | 5.5 (1.4-27.5)                              | 4.8 (1.2-24.3)                                         | 0.03            |
| Parkinson’s disease                         | 9/61 (14.8%)       | 1 (11.1%)       | 3.3 (0.2-29.8)                              | 3 (0.1-27.4)                                           | 0.37            |
| Functional neurological disorders            | 8/48 (16.7%)       | 1 (12.5%)       | 3.8 (0.2-34.7)                              | 4.7 (0.2-43.6)                                         | 0.21            |
| Cerebellar disorders                        | 21/39 (53.8%)      | 12 (57.1%)      | 35.6 (9.4-179.9)                            | 33.9 (8.9-172.3)                                       | 0.00            |
| Headache                                    | 11/35 (31.4%)      | 4 (36.4%)       | 15.2 (2.8-92)                               | 14.4 (2.7-88.7)                                        | 0.00            |
| Dementia                                    | 7/20 (35%)         | 0 (0%)          | 0 (0-0)                                     | 0 (0-0)                                                 | 0.99            |
| Demyelinating disease                       | 12/15 (80%)        | 0 (0%)          | 0 (0-0)                                     | 0 (0-0)                                                 | 0.98            |

**Footnote:** Includes logistic regression odds ratio and adjusted odds ratio (a OR), adjusted for age and sex compared to the baseline group of space occupying lesions. The p-value for the Wald test for each category is also presented.

*missing values, ages=20, sex=4.*
| Disorder | Diagnosis | Frequency (%) | *Median age (IQR) | HIV positive (%) | *Male (%) | *Female (%) |
|----------|-----------|---------------|-------------------|------------------|------------|-------------|
| Cerebrovascular disease | Cerebrovascular accident | 286 (14%) | 56.5 (42-68) | 24 (27.3%) | 186 (65%) | 100 (35%) |
| Subdural haematoma | 60 (2.9%) | 62 (51-76) | 0 (0%) | 44 (73.3%) | 16 (26.7%) |
| Subarachnoid haemorrhage | 25 (1.2%) | 38 (25-53) | 2 (16.7%) | 6 (24%) | 19 (76%) |
| Others | 35 (1.7%) | 33 (25-56) | 0 (0%) | 16 (45.7%) | 19 (54.3%) |
| Infection: Intracerebral abscess | Toxoplasmosis | 47 (2.3%) | 37 (30-46) | 47 (100%) | 15 (31.9%) | 2 (68.1%) |
| Tuberculosis | 10 (0.5%) | 30 (28-36) | 6 (60%) | 5 (45.5%) | 6 (54.5%) |
| Infection: Meningitis/Encephalitis | T8 meningitis | 44 (2.2%) | 33 (27-39) | 16 (39%) | 30 (68.2%) | 14 (31.8%) |
| Cryptococcal meningitis | 34 (1.7%) | 35 (30-41) | 33 (100%) | 16 (47.1%) | 18 (52.9%) |
| Bacterial meningitis | 25 (1.2%) | 25 (22-38) | 6 (33.3%) | 16 (64%) | 9 (36%) |
| Viral meningoencephalitis | 7 (0.3%) | 38 (19-55) | 1 (16.7%) | 4 (57.1%) | 3 (42.9%) |
| Infection: Cerebral Malaria/ TETANUS/ Others | Tetanus | 20 (1%) | 39 (25-75-49.75) | 0 (0%) | 17 (85%) | 3 (15%) |
| Cerebral Malaria | 17 (0.8%) | 28 (20-31) | 1 (9.1%) | 10 (62.5%) | 6 (37.5%) |
| Others | 20 (1%) | 35.5 (21.75-56) | 8 (50%) | 13 (65%) | 7 (35%) |
| Paraplegia | Malignancy spinal cord | 73 (3.6%) | 57 (43-70) | 3 (9.1%) | 50 (68.5%) | 23 (31.5%) |
| Paraplegia | 65 (3.2%) | 45.5 (30-55) | 10 (41.7%) | 28 (43.7%) | 36 (56.2%) |
| Transverse myelitis | 37 (1.8%) | 30 (20-38) | 1 (4.5%) | 18 (48.6%) | 19 (51.4%) |
| Quadriplegia | 24 (1.2%) | 57 (47.5-62.25) | 0 (0%) | 19 (79.2%) | 5 (20.8%) |
| Potts Disease | 23 (1.1%) | 36 (29-51.5) | 5 (35.7%) | 12 (52.2%) | 11 (47.8%) |
| Epidural abscess | 13 (0.6%) | 27 (17-35) | 0 (0%) | 8 (61.5%) | 5 (38.5%) |
| Syringomyelia | 12 (0.6%) | 48 (42-49) | 0 (0%) | 5 (41.7%) | 7 (58.3%) |
| Others | 31 (1.5%) | 34.5 (25.25-51.5) | 6 (33.3%) | 25 (80.6%) | 6 (19.4%) |
| Peripheral neuropathies | Hereditary Sensory Motor Neuropathies (HMSN) | 14 (0.7%) | 35 (30.25-53) | 3 (37.5%) | 8 (57.1%) | 6 (42.9%) |
| Subacute combined degeneration | 12 (0.6%) | 44 (37-49.25) | 0 (0%) | 5 (41.7%) | 7 (58.3%) |
| Mononeuritis multiplex | 10 (0.5%) | 38.5 (32.25-42.75) | 3 (60%) | 5 (50%) | 5 (50%) |
| Secondary and Others | 51 (2.5%) | 45 (35.5-55) | 11 (45.8%) | 22 (43.1%) | 29 (56.9%) |
| Brain tumours | Metastatic | 80 (3.9%) | 45 (34-61) | 2 (5.3%) | 50 (62.5%) | 30 (37.5%) |
| Glioma | 39 (1.9%) | 49 (28.25-62) | 0 (0%) | 22 (56.4%) | 17 (43.6%) |
| Meningioma | 21 (1%) | 41.5 (35-53.5) | 1 (6.7%) | 7 (35%) | 13 (65%) |
| Pituitary Tumour | 11 (0.5%) | 43 (39-49) | 0 (0%) | 7 (63.6%) | 4 (36.4%) |
| Others | 10 (0.5%) | 34.5 (39-46.25) | 0 (0%) | 4 (40%) | 6 (60%) |
| Cranial nerve palsies | Facial nerve palsy | 36 (1.8%) | 33 (25-48.5) | 7 (25.9%) | 21 (58.3%) | 15 (41.7%) |
| Optic neuritis | 21 (1%) | 40 (35-46) | 11 (61.2%) | 5 (23.8%) | 16 (76.2%) |
| III,IV,VI nerve palsy | 15 (0.7%) | 50 (36-58.5) | 12 (12.5%) | 7 (46.7%) | 8 (53.3%) |
| Trigeminal neuralgia | 15 (0.7%) | 48 (35.5-64) | 2 (66.7%) | 7 (46.7%) | 8 (53.3%) |
| Others | 11 (0.5%) | 41 (35-25-57) | 1 (16.7%) | 6 (54.3%) | 5 (45.5%) |
| Movement disorders | Dystonia | 31 (1.5%) | 43 (22-53) | 2 (18.2%) | 14 (45.2%) | 17 (54.8%) |
| Chorea | 15 (0.7%) | 62 (26-59) | 1 (33.3%) | 8 (53.3%) | 7 (46.7%) |
| Benign Essential Tremor | 13 (0.6%) | 67 (57-77) | 2 (100%) | 8 (61.5%) | 5 (38.5%) |
| Voluntary Movements | 12 (0.6%) | 43 (26-49.25) | 2 (33.3%) | 5 (41.7%) | 7 (58.3%) |
| Others | 19 (0.9%) | 35 (31-54) | 2 (28.6%) | 11 (57.9%) | 8 (42.1%) |
| Neuromuscular disorders | Myasthenia gravis | 25 (1.2%) | 33 (21-43) | 0 (0%) | 10 (40%) | 15 (60%) |
| Dermatomyositis | 15 (0.7%) | 40 (36-54.5) | 1 (10%) | 5 (33.3%) | 10 (66.7%) |
| Stiff person syndrome | 9 (0.4%) | 45 (37-48) | 1 (14.3%) | 5 (55.6%) | 4 (44.4%) |
| Limb girdle dystrophy | 6 (0.3%) | 24.5 (15.25-30.75) | 0 (0%) | 5 (83.3%) | 1 (16.7%) |
| Facio scapulo humeral dystrophy | 4 (0.2%) | 16.5 (14.5-19.75) | 0 (0%) | 3 (75%) | 1 (25%) |
| Others | 13 (0.6%) | 32 (25-37) | 1 (12.5%) | 5 (38.5%) | 8 (61.5%) |
There were differences between those who were and were not tested for HIV. The mean age for those tested was younger at 39.9 years, compared to 48.5 years for those not tested (t-test statistic 10.4, p<0.05). The unadjusted odds ratio of being tested for HIV in men compared to women was 0.81, 95% CI 0.68-0.97 (p = 0.02); suggesting that men were 19% less likely to be tested for HIV than women.

### Discussion

This study reports a large series of adult patients presenting with NDs and their association with HIV infection. The most common NDs in the series were cerebrovascular disease, infections and paraplegia followed by neuropathies, space occupying lesions tumours and seizures, a pattern largely similar to that reported in other hospital based studies in SSA

| Table | Amyotrophic lateral sclerosis | Pseudobulbar palsy | Progressive muscular atrophy | Primary lateral sclerosis | Parkinson’s disease | PD plus syndrome | Altered state of consciousness | Functional neurological disorders | Headache | Dementia | Demyelinating disease |
|-------|-------------------------------|--------------------|-------------------------------|--------------------------|---------------------|------------------|-----------------------------|-----------------------------|----------|-----------|---------------------|
|       | 42 (2.1%)                     | 10 (0.5%)          | 10 (0.5%)                     | 6 (0.3%)                 | 56 (2.7%)           | 5 (0.2%)         | 47 (2.3%)                   | Functional paralysis           | 10 (0.5%) | 13 (6.0%) | 9 (0.4%)           |
|       | 50.5 (40.25-63.5)             | 70 (56.25-74.5)    | 53.5 (49-65.75)               | 60.5 (53.25-67.75)       | 60 (52.75-70.5)     | 74 (71-75)       | 40 (25-52.5)                | Psychogenic non-epileptic attacks | 17 (0.8%) | 19 (6-30) | 1 (0%)             |
|       | 4 (16.7%)                     | 0 (0%)             | 1 (16.7%)                     | 1 (33.3%)                | 1 (14.3%)           | 0 (0%)           | 2 (8.7%)                   | Globus hystericus               | 1 (0%)    | 27 (27-72) | 0 (0%)             |
|       | 4 (16.7%)                     | 3 (17.6%)          | 34 (72.3%)                    | 11 (68.8%)               | 0 (0%)              | 8 (72.7%)        | 11 (16.3%)                 | Generalised Seizures            | 114 (5.6%) | 33 (21.48) | 54 (47.4%)         |
|       | 21 (51.2%)                    | 1 (100%)           | 13 (27.7%)                    | 5 (31.3%)                | 10 (16.7%)          | 3 (27.3%)        | 15 (45.5%)                 | Others                       | 37 (0.8%) | 27 (17-39) | 9 (52.9%)          |
|       | 20 (48.8%)                    | 10 (33.3%)         | 12 (33.3%)                    | 11 (6.2%)                | 18 (51.4%)          | 5 (31.3%)        | 1 (16.3%)                  | Cerebellar Ataxia               | 35 (1.7%) | 49 (26-58) | 17 (48.6%)         |
|       |                               |                    |                               |                          |                     | 4 (0.2%)         | 4 (0.2%)                   | Friedreich’s ataxia             | 4 (0.2%)  | 32 (21.7-45.75) | 3 (75%)          |
|       |                               |                    |                               |                          |                     | 10 (1%)          | 1 (100%)                   | Idiopathic intracranial hypertensive | 10 (0.5%) | 28.5 (24.5-38.25) | 9 (0%)             |
|       |                               |                    |                               |                          |                     | 1 (100%)        | 1 (100%)                   | Cluster headache                | 9 (0.4%)  | 38 (33-41)  | 8 (88.9%)          |
|       |                               |                    |                               |                          |                     | 1 (100%)        | 1 (100%)                   | Migraine                        | 8 (0.4%)  | 30 (20.25-38.5) | 8 (88.9%)          |
|       |                               |                    |                               |                          |                     | 1 (100%)        | 1 (100%)                   | Others                         | 8 (0.4%)  | 27.5 (21-31.75) | 8 (88.9%)          |
|       |                               |                    |                               |                          |                     | 1 (100%)        | 1 (100%)                   | Dementia                        | 13 (0.6%) | 67 (59-70)  | 7 (53.8%)          |
|       |                               |                    |                               |                          |                     | 1 (100%)        | 1 (100%)                   | Frontal lobe                    | 5 (0.2%)  | 60 (56-72)  | 3 (60%)            |
|       |                               |                    |                               |                          |                     | 1 (100%)        | 1 (100%)                   | Others                         | 2 (0.1%)  | 70 (60-79)  | 1 (50%)            |
|       |                               |                    |                               |                          |                     | 1 (100%)        | 1 (100%)                   | Neumyelitis Optica              | 9 (0.4%)  | 25 (19-30)  | 3 (33.3%)          |
|       |                               |                    |                               |                          |                     | 1 (100%)        | 1 (100%)                   | Acute demyelinating encephalomyelitis | 4 (0.2%)  | 15.5 (13-18.75) | 2 (50%)            |
|       |                               |                    |                               |                          |                     | 1 (100%)        | 1 (100%)                   | Multiple Sclerosis              | 2 (0.1%)  | 21 (17-25)  | 2 (50%)            |

Footnote *missing values, ages=20, sex=4

The results of HIV testing were available for 48.7% of patients of whom 30.6% were seropositive. Similar high rates of HIV seropositivity, 15.4-33.3% have been reported previously in patients presenting with NDs in SSA.

NDs in this series significantly associated with HIV.
included cerebrovascular disease, infections, paraplegia, peripheral neuropathies, cranial nerve palsies, seizure disorders, movement disorders, motor neurone disease, cerebellar disorders, and headache with adjusted odds ratio ranging from 107 in cerebral abscess to 4.8 in motor neurone disease.

The finding of a lower mean age of 39.9 years in those screened for HIV infection versus 48.5 years in those not screened and with females more likely to be screened than males suggests there was a clinical selection bias towards screening patients who were more likely to be seropositive. A significant limitation in the present study is that HIV screening was carried out in less than half of all patients and there may have been a selection bias towards referral and inclusion of seropositive patients which may have altered results. An earlier study carried out at the same study site during the same study period involved HIV screening in a consecutive series of 337 adult patients presenting with neurological disorders reported a lower overall HIV seroprevalence of 20.5% with significant HIV association limited to CNS infections reported in the series and was significantly associated with HIV infection, OR 6.2. The main causes in the series were malignancy, transverse myelitis and Potts disease, with a group (35%) of undetermined aetiology, a pattern largely similar to that reported in other studies in Africa35. The association of paraplegia and HIV infection has been well documented in SSA, affecting a mostly younger age group (20-40 years) and with TB, syphilis and vacuolar myelopathy as the main causes36,20–24. A small number of patients in the series 0.7%, presented with central demyelinating neurological disorders, including neuromyelitis optica (NMO), acute demyelinating encephalomyelitis (ADEM) and multiple sclerosis (MS), and without an association with HIV. However NMO has been reported in a large series from South Africa with a significant association with HIV29. Multiple sclerosis is relatively uncommon in Africa and was reported in only two patients in the present series. In a detailed study in South Africa the age standardized prevalence rate of MS was reported as 0.23/100 000 in the black population was as compared to 25.64/100,00 in the white population30.

Peripheral neuropathies accounted for 8% in the series and was associated with HIV infection, OR 10.5. Neuropathy has been reported in other neurology studies in SSA with frequencies ranging from 10% in inpatients series and 2.2-13.8% in outpatients series4,9,10,16,31. The most common neuropathy in HIV in SSA is distal sensory neuropathy with reported frequencies in HIV in SSA ranging from 4-64% largely depending on diagnostic criteria used, including HIV stage and antiretroviral therapy32–35. While the present series included selected referred
patients with Guillain-Barré syndrome (GBS), hereditary disorders and subacute combined degeneration, in the majority of patients the neuropathies were classified as either secondary to systemic disease or idiopathic. GBS was reported in 1.3% of patients with a HIV seropositive rate of 26.3% in those screened. The association of inflammatory neuropathies with HIV infection has been reported in SSA since early in the epidemic. Cranial nerve palsies accounted for 4.8% of NDs in the series and were associated with HIV infection, OR 13.9. The association was strongest for facial nerve palsy and optic neuritis, a pattern previously reported in associated with HIV infection in SSA.

Movement disorders 4.4%, and Parkinson's disease 3%, which was categorised separately, together accounted for a total of 7.4% of NDs in the series. The category movement disorders included dystonia, chorea, benign essential tremor and writer's cramp, a pattern largely similar to that reported elsewhere in SSA. In this series movement disorders were significantly associated with HIV infection, OR 11.2. While movement disorders in HIV infection may occur as a result of CNS opportunistic infections they may also occur as a result of the direct effects of HIV infection involving the brain. Parkinson's disease in the series was not associated with HIV. It typically affected mostly older males, a pattern similar to that reported elsewhere in SSA.

Brain tumours accounted for 7.9% of NDs in the series and had a low overall HIV prevalence rate of 3.6%. The main pattern, metastatic, glioma, meningioma and pituitary tumours is similar to that reported in other series in Africa. The frequency of primary CNS lymphoma, the most common brain tumour in HIV is known to be low in SSA where the confirmed autopsy rate ranges from 0 to 1.3%.

Neuromuscular disorders accounted for 3.5% of NDs in the series and were not significantly associated with HIV, OR 2.1. They comprised of myasthenia gravis, dermatomyositis/polymyositis, stiff person syndrome, muscular dystrophy, and others. An association of dermatomyositis/polymyositis with HIV has been reported in SSA. Stiff person syndrome is a very rare neuromuscular disorder and a more detailed analysis of the cases reported in the present case series has been published elsewhere.

The neuromuscular disease category included limb girdle and fascio scapula humeral muscular dystrophy and the first genetically confirmed case of Becker muscular dystrophy in Tanzania.

Motor neuron disease (MND) comprised 3.3% in the series and was significantly associated with HIV infection, OR 4.8. A recent publication from Tanzania involving 116 MND patients including patients from the present series describes the full clinical spectrum of MND and their significant association with HIV. It also includes a brief report of a patient who presented with symptomatic HIV and new onset concurrent amyotrophic lateral sclerosis and was treated with antiretroviral treatment (ART) and survived for over 10 years. The association between HIV and MND is more strongly confirmed in a recent study from South Africa involving a cohort of 35 HIV positive MND patients with a similar reported 10 year survival of 48% in the ART treated cohort versus 3% in the HIV uninfected MND cohort. This novel association of MND with HIV and apparent response of MND to ART is reviewed in a recent editorial suggesting the reactivation of latent retroviral infection as the likely aetiological agent in HIV associated MND.

Seizure disorders comprised 6.4% of NDs in the series and were significantly associated with HIV infection, OR 15.7. A high burden of seizure disorders with frequencies ranging from 6-12.6% is reported in similar hospital based studies in adults in SSA. The added burden of seizures in HIV in SSA is reflected by their reported high frequency in HIV infection, occurring in up to 10% of patients presenting with advanced immunosuppression, with OIs as their main cause. Impaired level of consciousness was present in 3.6% in the series and was not associated with HIV infection, OR 2.9. It is associated with a poor prognosis in SSA, with reported in hospital case fatality rates ranging from 26-76% typically reflecting the seriousness of the underlying cause.

Cerebellar disorders accounted for 1.9% of NDs in the series including hereditary and idiopathic and were significantly associated with HIV infection, OR 33.9. The main causes of cerebellar disease in HIV are focal opportunistic processes involving the cerebellum including toxoplasmosis and progressive multifocal leukoencephalopathy and less frequently CNS lymphoma. However...
less well known are chronic effects of direct HIV infection which can result in cerebellar atrophy and clinical disease.59.

Functional NDs accounted for 2.4% in the series and were characterised by a younger age group affected and female preponderance but without any association with HIV infection, OR 3.8. The main pattern of clinical presentations included loss of neurological function, psychogenic non-epileptic attacks, and movement disorders. A more detailed report of the patients reported in the present series and a review of the literature has been recently published.60

Headache accounting for 1.7% in the series included migraine, cluster headache and idiopathic intracranial hypertension and were significantly associated with HIV infection, OR 14.4. However the sample size reported is small and an underestimate of their true burden with most cases either not referred for neurological consultation or reported. The burden of headache globally is known to be large affecting as many as 3 billion persons, with almost 2 billion with tension headache and 1 billion with migraine.61 Studies in SSA suggest that the burden and pattern of headache is largely similar to that reported in high income countries.62–64 A small series of predominantly male patients presented with cluster headache and while it has been reported in SSA it appears to be relatively uncommon there.65 Idiopathic intracranial hypertension occurred almost exclusively in younger, (median age 28.5 years), females (90%) and has been reported elsewhere in SSA.66

Dementia represented just 1% of NDs in this series study and characteristically affected an older age group, (median age 67 years) and was not associated with HIV. The low frequency of dementia reported in the present series is likely to be a significant underestimate of the true burden as most cases were either not recognized, referred, or reported. The Global Burden of dementia is large with an age standardized prevalence rate of 712/100,000 and an estimated global burden of almost 44 million cases.67 Dementia is reported in neurology studies in SSA as occurring with a wide range of frequencies ranging from 0-11%68, 69. An age standardized community prevalence in those aged 70 and over in Northern Tanzania, none of whom had been previously diagnosed, was reported as 6.4% (CI 4.9-7.9), a frequency comparable to that reported in HICs.70 While the main causes of dementia are Alzheimer’s and cerebrovascular disease, the added burden of HIV associated neurocognitive disorders (HAND) coupled with an increasingly aging population makes it likely that SSA will experience a high frequency of dementia in the future.71

The outcome is not reported in this case series. However an earlier study involving a consecutive series of 337 adult neurology inpatients at the same study site and during the same study period reported that the outcome at discharge was death 27.6%, disability 54%, and no disability 18.4%, with death, 39.1% more likely in seropositive patients.5 Case fatality rates were highest for tetanus 71.4%, meningitis 57.1%, cerebral malaria 42.9% and other CNS infections 37.1%. Patients with stroke, paraplegia and space occupying lesions were more likely to be discharged with disability.

Limitations
This paper has some limitations. There is likely to be selection bias as the series represents tertiary referrals to a specialist neurology service, the only such service serving 16 million persons. It is likely biased towards the more uncommon neurological diseases, such as motor neuron disease and space occupying lesion and diagnoses which benefit from specialist opinion and diagnostics such as neuroimaging. Conversely, the neurological diseases which local services are more used to managing independently such headache, and diseases which may not present due to reduced awareness, such as dementia, are less well represented in the series.

This study does not aim to differentiate between inpatient and outpatients but rather present an overview of a tertiary service. There is likely to be differences in these groups which would merit further and more detailed investigation. Rates of HIV testing differed by disorders and the epidemiological characteristics of those tested differed from those not tested. The adjusted odds ratios of HIV infection should therefore be interpreted with significant caution as a differential bias may have occurred. Nevertheless, broadly rates of HIV infection appear high and the significant odds ratio between not only opportunistic infections, but also in other NDs conditions such as stroke and paraplegia support a conclusion that HIV is associated with these diseases.

Finally, given the relative absence of more detailed laboratory and neuroradiological diagnostic facilities, and
sub-specialty referral there may be concerns regarding the accuracy of diagnosis. The ND/diagnoses categories used represents best clinical practice in the study setting and more detailed clinical characteristics missing in this present study are addressed in the separate published nested study.

Conclusion
This hospital-based study reports a large series of NDs and diseases in adults in Tanzania and describes their main pattern of demographics and categorization. The study reports a significant association of a range of NDs with HIV infection including stroke, infections, paraplegia, neuropathies, cranial nerve palsies, movement disorders, motor neuron disease, seizures, cerebellar disease, and headache. It is likely that HIV will continue to influence the pattern of NDs in SSA for the foreseeable future. Routine screening for HIV is recommended for patients presenting with NDs.

Abbreviations
ADEM: Acute Demyelinating Encephalomyelitis; aOR: Adjusted Odds Ratio; ART: Antiretroviral treatment; CNS: Central Nervous System; CI: Confidence Intervals; CT: Computerized Tomography; DALYS: Disability-Adjusted Life Years; DSN: Distal Sensory Neuropathy; GBS: Guillain-Barré syndrome; HAND: HIV Associated Neurocognitive Dysfunction; HIV: Human Immunodeficiency Virus; IQR: Interquartile range; KCMC: Kilimanjaro Christian Medical Centre; MND: Motor Neurone Disease. MRI: Magnetic Resonance Imaging; MS: Multiple Sclerosis; ND: Neurological Disorders; NMO: Neuromyelitis Optica; NCD: Non-communicable Diseases; OI: Opportunistic infection; SAH: Sub Arachnoid Haemorrhage; SDH: Subdural Haematoma; SSA: Sub-Saharan Africa; VM: Vacuolar Myelopathy.

Acknowledgments
We would like to thank the patients and staff at KCMC for making this study possible. In particular we would like to thank Mr G Kapanda for his help with data presentation.

Authors’ contributions
All the authors have read and approved the manuscript. The study concept, design, data collection analysis and interpretation and drafting the manuscript was carried out by WPH and assisted by MCD. Data collection was assisted by SJU, VPM and RGK. PJH assisted with data review, statistical analysis, and interpretation. RWW did a critical revision of the manuscript for important intellectual content.

Ethics approval
The study was approved by the appropriate ethics committee certificate number 817 and performed in accordance with ethical standards. Permission to conduct the study was obtained from the head of the medical department and KCMC. Confidentiality was adhered to by using codes instead of names for identifying patients.

Conflict of interests
The authors declare that they have no conflict of interests. No funding was involved in the study.

References
1. Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:459–80.
2. Bower JH, Asmera J, Zebenigus M, Sandroni P, Bower S, Zenebe G. The burden of inpatient neurologic disease in two Ethiopian hospitals. Neurology. 2007;68:338–42.
3. Chin JH, Vora N. The global burden of neurologic diseases. Neurology. 2014;83:349–51.
4. Siddiqi OK, Atadzhanov M, Birbeck GL, Koralnik IJ. The spectrum of neurological disorders in a Zambian tertiary care hospital. J Neurol Sci. 2010;290:1–5. doi:10.1016/j.jns.2009.12.022.
5. Laizer S, Kilonzo K, Urasa S, Maro V, Walker R, Howlett W. Neurological disorders in a consultant hospital in Northern Tanzania. A cohort study. eNeurological Sci. 2019;14 September 2015:101–5. doi:10.1016/j.eNSci.2018.11.013.
6. Lekoubou A, Echouffo-tcheugui JB, Kengne AP. Epidemiology of neurodegenerative diseases in sub-Saharan Africa: a systematic review. BMC Public Health. 2014;14:1–32.
7. Diaz MM, Hu X, Fenton BT, Kimuli I, Lee A, Lindsey H, et al. Prevalence of and characteristics associated with in-hospital mortality in a Ugandan neurology ward. BMC Neurol. 2020;20:42. doi:10.1186/s12883-020-1627-5.
8. Tegueu CK, Nguefack S, Doumbe J, Fogang YF, Mbonda PC, Mbonda E. The spectrum of neurological
disorders presenting at a neurology clinic in Yaoundé, Cameroon. Pan Afr Med J. 2013;14. doi:10.11604/ panj.2013.14.148.2330.
9. Sarfo F, Akassi J, Badu E, Okorozo A, Owiafele B, Akpalu A. Profile of neurological disorders in an adult neurology clinic in Kumasi, Ghana. eNeurological Sci. 2016;3:69–74. doi:10.1016/j.eensci.2016.03.003.
10. Komolafe MA, Owagbemi AT. The Distribution and Pattern of Neurological Disease in a Neurology Clinic in Ile Ife, Nigeria. Niger J Clin Pract. 2018;21:1520–4.
11. Kaddumukasa M, Mugenyi L, Kaddumukasa MN, Ddumba E, Devereaux M, Furlan A, et al. Prevalence and incidence of neurological disorders among adult Ugandans in rural and urban Mukono district; a cross-sectional study. BMC Neurol. 2016;1:1–9. doi:10.1186/s12883-016-0732-y.
12. GBD 2016 Stroke Collaboration. Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:439–58.
13. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018;1789–858.
14. Howlett WP, Nkya WM, Mmuni KA, Missalek WR. Neurological disorders in AIDS and HIV disease in the northern zone of Tanzania. AIDS. 1989;3:289–96. doi:10.1097/00002030-198905000-00007.
15. Howlett WP. Neurological disorders in HIV in Africa: A review. Afr Health Sci. 2019;19:1953–77.
16. CK T, Nk S, Jacques Doumbe, Yannick Fogoum Fogang, Paul Chimi Mbonda EM. The spectrum of neurological disorders presenting at a neurology clinic in Yaoundé, Cameroon. Pan Afr Med J. 2013;14:1–6.
17. Walker RW, Jusabani A, Aris E, Gray WK, Unwin N, Swai M, et al. Stroke risk factors in an incident population in urban and rural Tanzania: a prospective, community-based, case-control study. Lancet Glob Heal. 2013;1:e282–8. doi:10.1016/S2214-109X(13)70068-8.
18. Abdallah A, Chang JL, Carroll CBO, Musubire A, Chow FC, Wilson AL, et al. Stroke in Human Immuno-deficiency Virus-infected Individuals in Sub-Saharan Africa (SSA): A Systematic Review. J Stroke Cerebrovasc Dis. 2018;27:1828–36.
19. Rashid SM, Delirian SS, Dekker MCJ, Howlett WP. Chronic subdural hematomas: a case series from the medical ward of a north Tanzanian referral hospital. Egypt J Neurosurg. 2019;34:29. PubMed doi:10.1186/s41984-019-0054-7.
20. Jarvis JN, Meintjes G, Williams A, Brown Y, Crede T, Harrison TS. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis. 2010;10:67. doi:10.1186/1471-2334-10-67.
21. Cox JA, Lukande RL, Lucas S, Nelson AM, Van Marck E, Colebunders R. Autopsy causes of death in HIV-positive individuals in sub-Saharan Africa and correlation with clinical diagnoses. AIDS Reviews. 2010;12:183–94.
22. Lewden C, Drabo YJ, Zannou DM, Maiga MY, Minta DK, Sow PS, et al. Disease patterns and causes of death of hospitalized HIV-positive adults in West Africa: A multicountry survey in the antiretroviral treatment era. J Int AIDS Soc. 2014;17. doi:10.7448/IAS.17.1.18797.
23. Veltman JA, Bristow CC, Klausner JD. Meningitis in HIV-positive patients in sub-Saharan Africa: a review. J Int AIDS Soc. 2014;17:19184. doi:10.7448/IAS.17.1.19184.
24. Tenforde MW, Gertz AM, Lawrence DS, Wills NK, Guthrie BL, Farquhar C, et al. Mortality from HIV-associated meningitis in sub-Saharan Africa: a systematic review and meta-analysis. J Int AIDS Soc. 2020;23:e25416. doi:10.1002/jia2.25416.
25. Musubire AK, Meya DB, Katabira ET, Meyer ACL, Bohjanen PR, Boulware DR, et al. Epidemiology of non-traumatic spinal cord injury in Uganda: a single center, prospective study with MRI evaluation. BMC Neurol. 2019;19:10. doi:10.1186/s12883-019-1236-3.
26. Bhigjee I, Madurai S, Bill PL, Patel V, Corr P, Naidoo MN, et al. Spectrum of myelopathies in HIV seropositive South African patients. Neurology. 2001;57:348–51.
27. Modi G, Ranchhod J, Hari K, Mochan A MM. Non-traumatic myelopathy at the Chris Hani Baragwanath Hospital, South Africa—the influence of HIV. JFM. 2011;104:697–703.
28. Musubire AK, Meya, David B, Musubire AK, Meya DB, Bohjanen PR, Katabira ET, Barasukana P, et al. Systematic review of non-traumatic spinal cord injury in sub-Saharan Africa and a proposed diagnostic algorithm for resource-limited settings. Frontiers in Neurology. 2017;8:1–12.
29. Bhigjee AI, Moodley AA, Roos I, et al. The neuromyelitis optica presentation and the aquaporin-4 antibody in HIV-seropositive and seronegative patients in KwaZulu-Natal, South Africa. South Afr J HIV Med. 2017;18:1–7. doi:10.4102/sajhivmed.v18i1.684.
30. Bhigjee AI, Moodley K, Ramkisson K. Multiple sclerosis in KwaZulu Natal, South Africa: An epidemiological and clinical study. *Mult Scler.* 2007;13:1095–9. doi:10.1177/1352458507079274.

31. Callixte K, Clet TB, Jacques D, Faustin Y, François DJ, Maturin T. The pattern of neurological diseases in elderly people in outpatient consultations in Sub-Saharan Africa. *BMC Res Notes.* 2015;8. doi:10.1186/s13104-015-1116-x.

32. Mullin S, Temu A, Kalluvya S, Grant A, Manji H. High prevalence of distal sensory polyneuropathy in antiretroviral-treated and untreated people with HIV in Tanzania. *Trop Med Int Heal.* 2011;16:1291–6.

33. Centner CM, Bateman KJ, Heckmann JM. Manifestations of HIV infection in the peripheral nervous system. *The Lancet Neurology.* 2013;12:295–309.

34. Maritz J, Benatar M, Dave JA, Harrison TB, Badri M, Levitt NS, et al. HIV neuropathy in South Africans: frequency, characteristics, and risk factors. *Muscle Nerve.* 2010;41:599–606. doi:10.1002/mus.21535.

35. Saylor D, Nakigozi G, Nakasujja N, Robertson K, Gray RH, Waver MJ, et al. Peripheral neuropathy in HIV-infected and uninfected patients in Rakai, Uganda. *Neurology.* 2017;89:485–91. doi:10.1212/WNL.0000000000004136.

36. Thornton CA, Latif AS, Emmanuel JC. Guillain-Barré syndrome associated with human immunodeficiency virus infection in Zimbabwe. *Neurology.* 1991;41:812–5. http://www.ncbi.nlm.nih.gov/pubmed/2046921

37. Howlett WP, Vedeler CA, Nyland H, Aarli JA. Guillain-Barré syndrome in northern Tanzania: a comparison of epidemiological and clinical findings with western Norway. *Acta Neurol Scand.* 1996;93:44–9. doi:10.1111/j.1600-0404.1996.tb00169.x.

38. Mochan A, Anderson D, Modi G. CIDP in a HIV endemic population: A prospective case series from Johannesburg, South Africa. *J Neurol Sci.* 2016;363:39–42.

39. Belec L, Georges AJ, Bource P, Schuller E, Vuillecard E, Di Costanzo B, et al. Peripheral facial nerve palsy related to HIV infection: relationship with the immunological status and the HIV staging in Central Africa. *Cent Afr J Med.* 1991;37:88–93.

40. Komolafe M, Fatusi O, Alatise O, Komolafe E, Amusa Y, Adeolu A, et al. The role of human immunodeficiency virus infection in infranuclear facial paralysis. *J Natl Med Assoc.* 2009;101:361–6.

41. Okubadejo NU, Bankole IA, Ojo OO, Ojini FI, Danesi MA. Prevalence of essential tremor in urban Lagos, Nigeria: a door-to-door community-based study. *BMC Neurol.* 2012;12:1. PubMed doi:10.1186/1471-2377-12-110.

42. Cubo E, Doumbe J, Njankouo YM, Nyinyikua T, Kuate C, Ouyang B, et al. The Burden of Movement Disorders in Cameroon: A Rural and Urban-Based Inpatient / Outpatient Study. *Mov Disord Clin Pract.* 2017;March:568–73.

43. Dotchin C, Msuya O, Kissima J, Massawe J, Mhina A, Moshy A, et al. The prevalence of Parkinson's disease in rural Tanzania. *Mov Disord.* 2008;23:1567–72.

44. Dorsey ER, Elbaz A, Nichols E, Abd-Allah F, Abdelalim A, Adsuar JC, et al. Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* 2018;17:939–53. doi:10.1016/S1474-4422(18)30295-3.

45. Williams U, Bandmann O, Walker R. Parkinson’s Disease in sub-Saharan Africa: A Review of Epidemiology, Genetics and Access to Care. 2018;11:53–64.

46. Heckmann JM, Pillay K, Hearn AP, Kenyon C. Polymyositis in African HIV-infected subjects. *Neuromuscul Disord.* 2010;20:735–9. doi:10.1016/j.nmd.2010.06.007.

47. Dekker MCJ, Urasa SJ, Kinabo G, Maro V, Howlett WP. A Report of Stiff Person Syndrome in Tanzania with First Epidemiological Figures for sub-Saharan Africa. *Neuropediatrics.* 2015;45:109–10.

48. Dekker MCJ, Tieleman AA, Igogo OJ, van Duyvenvoorde HA, Howlett WP, Hamel BC. First familial Becker muscular dystrophy in Tanzania: Clinical and genetic features. *Neuromuscul Disord.* 2019;29:317–20. doi:10.1016/j.nmd.2019.01.006.

49. Dekker MCJ, Urasa SJ, Aerts MB, Howlett WP. Motor neuron disease in sub-Saharan Africa: case series from a Tanzanian referral hospital. *J Neurol Neurosurg Psychiatry.* 2018;89:1349–50. doi:10.1136/jnnp-2017-317858.

50. Moodley K, Bill PLA, Bhigjee AI, Patel VB. *Journal of the Neurological Sciences.* A comparative study of motor neuron disease in HIV-infected and HIV-uninfected patients. *J Neurol Sci.* 2019;397 October 2018:96–102. doi:10.1016/j.jns.2018.12.030.

51. Mochan A. HIV related motor neuron disease/syndrome: The - potentially treatable - retroviral link in ALS? *J Neurol Sci.* 2019;397:75–6. doi:10.1016/j.jns.2018.12.029.

52. Assadeck H, Toudou Daouda M, Moussa Konate M, Mamadou Z, Hassane Djibo F, Douma Maiga D, et al. Clinical and etiological characteristics of epilepsy in people from Niger: a hospital based study from a tertia-
ry care referral center of Niamey, Niger. *Epilepsia Open*. 2019; April:318–27.
53. Modi M, Mochan A, Modi G. New onset seizures in HIV–seizure semiology, CD4 counts, and viral loads. *Epilepsia*. 2009;50:1266–9.
54. Siddiqi OK, Elafros MA, Bositis CM, Koralnik IJ, Theodore WH, Okulicz JF, et al. New-onset seizure in HIV-infected adult Zambians A search for causes and consequences. *Neurology*. 2017;88:477–82.
55. Obiako O, Ogunniyi A, Anyebe E. Prognosis of non-traumatic coma: The role of some socio-economic factors on its outcome in Ibadan, Nigeria. *Ann Afr Med*. 2009;8:115. PubMed doi:10.4103/1596-3519.56240.
56. Winkler AS, Tluway A, Schmutzhard E. Aetiologies of altered states of consciousness: A prospective hospital-based study in a series of 464 patients of northern Tanzania. *J Neurol Sci*. 2011;300:47–51. doi:10.1016/j.jns.2010.10.004.
57. Abdulkadir Mohamed M, Bekele N, Diro E, Shenkutie Greffie E, Landers T, Shibiru H, et al. Non-traumatic Coma: Causes and Outcomes of Adult Patients at University of Gondar Hospital, Northwest Ethiopia. *Clin Med Res*. 2015;4:198–203. doi:10.11648/j.cmr.20150406.16.
58. Modi G, Hari K, Modi M, Mochan A. The frequency and profile of neurology in black South African HIV infected (clade C) patients - A hospital-based prospective audit. *J Neurol Sci*. 2007;254:60–4.
59. Klunder AD, Chiang MC, Dutton RA, Lee SE, Toga AW, Lopez OL, et al. Mapping cerebellar degeneration in HIV/AIDS. *Neuropsych*. 2008;19:1655–9.
60. Dekker MCJ, Urasa SJ, Kellogg M, Howlett WP. Psychogenic non-epileptic seizures among patients with functional neurological disorder: A case series from a Tanzanian referral hospital and literature review. *Epilepsia Open*. 2018;3:66–72.
61. Collaborators G 2016 H. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*. 2018;17:954–76.
62. Winkler AS, Stelzhammer B, Kerschbaumsteiner K, MeindlM, DentW, KaayaJ, et al. The prevalence of headache with emphasis on tension-type headache in rural Tanzania: A community-based study. *Cephalalgia*. 2009;29:1317–25.
63. Woldeamanuel YW, Andreou AP, Cowan RP. Prevalence of migraine headache and its weight on neurological burden in Africa: A 43-year systematic review and meta-analysis of community-based studies. *J Neurol Sci*. 2014;342:1–15. doi:10.1016/j.jns.2014.04.019.
64. Mbewe E, Zairemthiama P, Yeh H-H, Paul R, Birbeck GL, Steiner TJ. The epidemiology of primary headache disorders in Zambia: a population-based door-to-door survey. *J Headache Pain*. 2015;16:30. doi:10.1186/s10194-015-0515-7.
65. Mengistu G, Alemayehu S. Prevalence and burden of primary headache disorders among a local community in Addis Ababa, Ethiopia. *J Headache Pain*. 2013;14:30. PubMed doi:10.1186/1129-2377-14-30.
66. Tagoe NN, Beyo VM, Amisah-Arthur KN. Case series of six patients diagnosed and managed for idiopathic intracranial hypertension at a tertiary institution eye centre. *Ghana Med J*. 2019;53:79. PubMed doi:10.4314/gmj.v53i1.12.
67. GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*. 2019;18:88–106.
68. Mavrodaris A, Powell J, Thorogood M. Prevalences of dementia and cognitive impairment among older people in sub-Saharan Africa: a systematic review. *Bull World Health Organ*. 2013;91:773–83.
69. De Jager CA, Msembali W, Pepper K, Combrinck MI. Dementia Prevalence in a Rural Region of South Africa: A Cross-Sectional Community Study. *J Alzheimer's Dis*. 2017;60:1087–96.
70. Longdon AR, Paddick SM, Kisoli A, Dotchins C, Gray WK, Dewhurst F, et al. The prevalence of dementia in rural Tanzania: A cross-sectional community-based study. *Int J Geriatr Psychiatry*. 2013;28:728–37.
71. Habib AG, Yaksai AM, Owolabi LF, Ibrahim A, Habib ZG, Gadaji M, et al. Neurocognitive impairment in HIV-1-infected adults in Sub-Saharan Africa: a systematic review and meta-analysis. *Int J Infect Dis*. 2013;17:e820–31. doi:10.1016/j.ijid.2013.06.011.